Cargando…
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Vanucizumab is a novel bispecific antibody inhibiting vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2) that demonstrated safety and anti-tumor activity in part I of a phase I study of 42 patients with advanced solid tumors. Part II evaluated the pharmacodynamic effects of vanuc...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749407/ https://www.ncbi.nlm.nih.gov/pubmed/33338877 http://dx.doi.org/10.1016/j.tranon.2020.100984 |